Esophageal cancer/Pleural effusion/Pericardial effusion/Radiotherapy/Chemoradiotherapy.
INTRODUCTION
Esophageal cancer is frequently diagnosed as a highly advanced stage. For patients with unresectable disease, definitive radiotherapy resulted in poor local control and low survival rates. 1) Hence, concurrent chemoradiotherapy (CCR) is now administered to advanced cases and achieves better outcomes and local control than radiotherapy alone. 2, 3) Because CCR has the advantage of greater functional preservation as compared with surgery, more patients with operable stage are selecting this method. [4] [5] [6] As a result of longer survival of patients after radiotherapy or CCR, cardio-pulmonary late adverse events have been recognized as an important issue. 7) In some cases, increasing effusion is difficult to control and can produce symptoms, such as dyspnea. We have experienced several cases requiring repeated drainage and previously reported a patient who died of cardiac tamponade. 8) Though cardiac and pulmonary late toxicities after irradiation have often been reported in breast cancer [9] [10] [11] and Hodgkin's lymphoma [12] [13] [14] cases, these toxicities are as yet poorly understood in esophageal cancer cases. In this study, we investigated the incidences and severities of pericardial and pleural effusions after definitive radiotherapy or CCR. Clinical and treatment-related risk factors for these adverse events are also discussed herein.
METHODS

Patient selection
From 2001 through 2005, 147 patients with primary thoracic or abdominal esophageal cancer received definitive radiotherapy or chemoradiotherapy (CCR) in our institute. Inclusion criteria were as follows: newly diagnosed and receiving first treatment other than endoscopic mucosal resection (EMR); thoracic or abdominal primary site; follow-up of at least 6 months; conventional fractionation and irradiation exceeding 50 Gy; World Health Organization (WHO) performance status ≤ 2, absence of pretreatment pericardial and/or pleural effusion on CT. Clinical staging was based on the International Union against Cancer (UICC) fifth edition. Staging was evaluated by gastrointestinal fiberscope, barium follow-through and chest-abdominal comput-ed tomography (CT). Endoscopic ultrasonography and bronchoscopy were recommended to judge T stage but did not performed for all patients.
Treatment
Radiation was administered using a linear accelerator with a 6MV x-ray, 2 Gy per day, five times a week. Treatment planning was based on X-ray simulations. The isocenter was defined at the center of the field and body thickness. Dose evaluation point was the same as the isocenter. The initial field consisted of anterior-posterior 2-port irradiation including the primary esophageal lesion and regional lymph nodes for advanced cancer, while for early cases only the involved lesion with its margin (3 cm to cranio-caudal, 1 cm to lateral and anterior-posterior) was irradiated. After 46 Gy, an oblique 2-port field was delivered, limited to the involved lesion and avoiding the spinal cord, and the maximum dose was 60 Gy. Daily continuous infusion of 5-FU (200 mg/m 2 ) and drip infusion of CDDP (4 mg/m 2 ) were administered simultaneously on radiation days as concurrent chemotherapy. This treatment regimen was performed as an institutional review board-approved protocol.
Evaluation and follow-up
The periods of survival and onsets of pericardial and/or pleural effusions were determined after the completion of radiotherapy. Treatment responses were evaluated by chest and abdominal CT scans, barium follow through and gastrointestinal fiberscope, and biopsy if needed. Each 3-month evaluation included clinical examinations. CT and/or gastrointestinal fiberscope examinations were conducted every 6 months for 3 years. After 3 years, patients received clinical examinations approximately every 6 months and CT and/or gastrointestinal fiberscope examinations annually. We reviewed chest CT scans to assess the development of pericardial and pleural effusions. Patients with pathologically confirmed malignant effusions were excluded from the analysis. Adverse effects were graded according to the Common Toxicity Criteria of the Radiation Therapy Oncology Group.
15)
The following clinical factors were investigated for their associations with the appearance of effusion: age, gender, diabetes, hypertension, cardiac disease (coronary artery disease and atrial fibrillation), WHO performance status and drinking and smoking histories. Treatment-related factors were as follows: main disease location, T4 disease, type of treatment (CCR or radiotherapy alone), radiation field length and mediastinal radiation field width in the initial anteriorposterior field.
Statistical evaluation
The cumulative occurrence of effusion was demonstrated using a Kaplan-Meier curve. Patients without effusion were censored at death. Univariate and multivariate analyses were conducted to identify the independent factors of outcome. The variables that showed trend on univariate analysis (p < 0.10) were included in a multivariate analysis. Multivariate analysis was performed using the Cox hazard model. Twosided p values < 0.05 were considered to be statistically significant. Statistical analyses were performed using SPSS, version 17.0 (SPSS Inc. Chicago, Illinois, USA).
RESULTS
Patient selection
The following patients were ultimately excluded: died of primary disease within 6 months (n = 18); received induction chemotherapy prior to irradiation (n = 2), could not followup more than 6 months (n = 19). Characteristics of eligible patients (n = 108) are summarized in Table 1 . One patient with malignant pericardial effusion was excluded from analysis of pericardial effusion. Three patients with malignant pleural disease and 4 with pleural effusion after lung operation were excluded from analysis of pleural effusion. The median follow-up was 34 (range, 6 to 84) months. Overall survival of eligible patients is shown in Figure 1 .
Treatment
CCR was administered to 81 patients while the other 27 received radiation alone. Two patients were treated with 5-FU alone due to renal dysfunction and 3 received weekly drip infusions of docetaxel (15 mg/m 2 ) because they refused continuous infusion. In the group younger than 70 years of age (n = 65), 59 (91%) received CCR. Of the patients age 70 and older (n = 43), 32 (74%) received CCR. In the group with stage I (n = 51), 33 (65%) patients received CCR. In the group with stages II to IV (n = 57), 48 (84%) patients received CCR. Radiation doses of less than 60 Gy were administered to 5 patients. The initial radiation field lengths were as follows: 6-10 cm (n = 8), 11-15 cm (n = 33), 16-20 cm (n = 23), 21-25 cm (n = 14), 26-30 cm (n = 19), 31-35 cm (n = 8) and 36-40 cm (n = 3). The initial radiation field widths were as follows: 5 cm (n = 3), 6 cm (n = 11), 7 cm (n = 35), 8 cm (n = 41), 9 cm (n = 15) and 10 cm (n = 3).
Analysis for pericardial effusion
The number of patients eligible for the pericardial effusion analysis was 107. The crude rates of overall pericardial effusion and effusion exceeding grade 2 were 46 (43%) patients and 15 (14%) patients. Onsets of pericardial effusion ranged from 2 to 58 months, median 12 months. Onset of effusion as an event with a toxicity exceeding grade 2 ranged from 3 to 58 months, median 9 months, after treatment completion. The grades of the events in these patients were distributed as follows; 10 patients with grade 2, 2 with grade 3, 1 with grade 4 and 2 with grade 5. Figure 2 shows the incidence rates of pericardial effusion exceeding grade 1 and grade 2 toxicities. Results of univariate and multivariate analyses for pericardial effusion are shown in Table 2 . Multivariate analysis identified radiation field width as the only significant factor for pericardial effusions exceeding both grade 1 and 2. Radiation field length was selected as significant factor only for pericardial effusion more severe than grade 1. Diabetes and chemotherapy were selected as significant factors for pericardial effusion more than grade 1 by univariate analysis but were not independent factors. Figure  3 shows the incidence rate of pericardial effusion more than grade 2 according to radiation field width. Pericardial effusion was observed at a significant rate in the group with a radiation field width exceeding 8 cm.
Analysis for pleural effusion
The number of patients eligible for pleural effusion analysis was 101. Overall, pleural effusion was observed in 44 (44%) patients. Among these 44, 15 patients had effusion on the left side only, 3 on the right side only and 26 had bilat- Abbreviations: RT = radiotherapy; CCR = concurrent chemotherapy; Ut = Upper thoracic esophagus; Mt = Middle thoracic esophagus; Lt = Lower thoracic esophagus. 
Fig. 2.
Cumulative incidence rates of pericardial effusions of more than grade 1 and more than grade 2. Abbreviations: G1 = toxicity more than grade 1, G2 = toxicity more than grade 2.
eral effusions. More than grade 2 effusion was observed in 18 (18%) patients. Onsets of pleural effusion ranged from 1 to 65 months, median 15 months, after treatment completion. Onsets of events more than grade 2 ranged from 2 to 61 months, median 10 months, after treatment completion. Twenty-eight patients had synchronous pericardial and pleural effusions. The distribution of toxicities of grade 2 or more was as follows; 15 patients with grade 2 and 3 with grade 3. Figure 4 shows the incidence rates of pleural effusions exceeding grade 1 and grade 2 toxicities. Results of univariate and multivariate analyses for pleural effusion are shown in Table 3 . Multivariate analysis identified age, radiation field width and length as independent factors for pleural effusions exceeding both grade 1 and 2. T4 disease was identified as a significant risk factor for pleural effusion of more than grade 1. Figure 5 shows the incidence rate of pleural effusion of more than grade 2 according to radiation field width. Pleural effusion was observed at a significant rate in the group with a radiation field width exceeding 8 cm. Abbreviations: Ut = Upper thoracic esophagus; Mt = Middle thoracic esophagus; Lt = Lower thoracic esophagus; HR = hazard ratio; CI = confidence interval. 
Other late toxicities
We observed one patient with grade 3 pneumonia needed hospital admission. Other 3 patients with grade 2 pneumonia needed medication. Endoscopic dilatation was performed for esophageal stenosis in one patient.
DISCUSSION
We described the incidences and severities of pericardial and pleural effusions after definitive radiotherapy with or without chemotherapy in esophageal cancer. Risk factors for such events were investigated. Pleural or pericardial, including asymptomatic, effusions were recognized in nearly 45% of patients. In one-third of these patients, the effusions were at least grade 2. This incidence rate was higher than those reported previously. 16) This may be attributable to our maximum dose of 60 Gy, which is higher than those used in Western countries. 17) Effusions appeared after periods of variable length. Wei et al. 16) reported the median onset time of pericardial effusion to be 6 months, while in a Japanese study 7) symptomatic pericardial or pleural effusion appeared at approximately 18 months. In this study, the median onset time was 12 months. It is difficult to distinguish between subacute and delayed effusion, because either may persist. A few of our cases had effusions which disappeared without treatment. Subacute effusion appears to be due to pleural or cardiac inflammation (pleuritis or pericarditis) associated with edematous change, fibrotic thickening, and adhesion. [18] [19] [20] Further study including basic experiments is warranted to explain these phenomena. More patients had left-sided than right-sided pleural effusions. The location of the esophagus is a possible reason for this laterality. Our analysis is limited by the eligibility criteria of allowing only patients followed up more than 6 months, thus the ratio of early stage patients was comparatively high. We have thought such adverse events are in particular important for longer surviving patients, though these events would occur in one month after radiotherapy.
In the analyses of risk factors, radiation field width was Abbreviations: Ut = Upper thoracic esophagus; Mt = Middle thoracic esophagus; Lt = Lower thoracic esophagus; HR = hazard ratio; CI = confidence interval. identified as an independent risk factor for pericardial and pleural effusions, with severities exceeding both grade 1 and 2. Irradiation of a wide initial anterior-posterior field may result in a large volume and dose to the heart and mediastinum. Studies have examined mean dose parameters for pericardial effusion using dose-volume analysis. 16, 21) Our linear accelerator did not have a multileaf collimator (MLC) at the time of this study. The MLC is capable of reducing the radiation field width such that a smaller volume is irradiated and there is less radiation exposure of surrounding organs. Cominos et al. reported that, the cardiac volume received more than 45 Gy was significantly reduced with their 4-field technique. 22) Modern treatment techniques such as 3-dimensional conformal radiotherapy or intensity modulated radiotherapy have the potential to decrease the dose to organs at risk, though we must be cautious with increasing low dose irradiation to the lung. Other factors, including radiation field length, were identified as being significantly associated with pericardial effusion more than grade 1, suggesting the irradiated large volume to the heart. On the other hand, main disease location was not selected as significant factor. We speculate that majority of the Ut tumor patients had Mt disease and influenced the results. No independent clinical factors influencing pericardial effusion were identified in this study. On the other hand, age and T4 disease were selected as independent factors for pleural effusions as well as radiation field factors. We speculate that a patient's general and/ or disease status may influence this adverse event. Chemotherapy was not identified as a risk factor but indications for chemotherapy in the elderly should be determined with caution, to assure that healthy patients are selected to receive CCR. Both pericardial and pleural effusions were observed in a certain number of patients. Irradiation to the heart may affect pleural effusion development. These cause-effectinteractions are complex. Our study was retrospective, but we anticipate that future investigations with large numbers of subjects will further elucidate these relationships.
As conclusions, pericardial and pleural effusions are relatively frequent adverse events. The radiation field width of the mediastinum exceeding 8 cm is an important risk factor for these fluid collections. Although a large field is unavoidable for treating an advanced disease, it is important to try whether a smaller irradiated field can be adapted and to perform progress observation carefully.
